Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX) will be announcing its earnings results after the market closes on Monday, February 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $79.28 on Friday. The firm has a market cap of $7,020.00, a P/E ratio of -35.71, a PEG ratio of 13.72 and a beta of 0.26. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

In related news, Director Gary A. Lyons sold 5,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $83.08, for a total transaction of $415,400.00. Following the completion of the sale, the director now directly owns 267,066 shares of the company’s stock, valued at $22,187,843.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the sale, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,707 shares of company stock valued at $14,975,715. Company insiders own 4.80% of the company’s stock.

A hedge fund recently raised its stake in Neurocrine Biosciences stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,665 shares of the company’s stock after purchasing an additional 193 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Neurocrine Biosciences were worth $123,000 at the end of the most recent quarter.

A number of analysts have recently weighed in on NBIX shares. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC upped their price target on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $76.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Oppenheimer set a $95.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, January 15th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $82.31.

COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Monday” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/neurocrine-biosciences-nbix-to-release-quarterly-earnings-on-monday.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit